ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1783

Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis

Marcos Chiñas1, Daniela Fernandez-Salinas1, Vitor Aguiar1, Victor Caballero-Nieto2, Micah Lefton3, Joerg Ermann4 and Maria Gutierrez-Arcelus1, 1Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Montpellier, France, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Ankylosing spondylitis (AS), genetics, genomics, Natural Killer Cells, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Multiple lines of evidence indicate that ankylosing spondylitis (AS) is a lymphocyte-driven disease. However, which lymphocyte populations are critical in AS pathogenesis is not known. AS is a highly heritable disease, with estimates of the genetic contribution to AS ranging from 69 to 90%. Genome-wide association studies (GWAS) have identified >100 loci associated with AS, with the vast majority of likely causal variants being non-coding. In this study, we aimed to identify the key cell types mediating the genetic risk in AS using an unbiased multi-omics approach.

Methods: We integrated GWAS data with epigenomic and transcriptomic datasets in human lymphocytes to identify key cell subsets mediating genetic susceptibility to AS. We used public ATAC-seq on sorted peripheral immune cell subsets of healthy subjects, low-input RNA-seq on 7 sorted lymphocyte populations of healthy subjects, and single-cell RNA-seq from the human gut single-cell atlas. To link cell type-specific open chromatin regions or gene expression with GWAS we used 3 published methods: Linkage Disequilibrium Score-regression in Specifically Expressed Genes (LDSC-seg), SNPsea, and single-cell disease-relevance score (scDRS). We validated that these methods could identify T-cells as the main drivers of Rheumatoid Arthritis. Additionally, we performed co-localization analyses between GWAS loci and genetic variants associated with gene expression (eQTL) to find putative target genes of AS risk variants.

Results: LDSC-seg revealed that NK-specific open chromatin regions are significantly enriched in heritability for AS, while this was not the case for other cell types such as T cells, B cells, and monocytes. This finding was consistent between two AS GWAS, one using the ImmunoChip, and the other (UK biobank) using a genome-wide chip. Applying SNPsea to RNA-seq data, we validated that genes in AS risk loci are enriched in NK cell-specific gene expression, compared to 6 T cell subsets (CD4+ T, CD8+ T, MAIT, iNKT, and two gamma delta T cell subsets). Gene expression levels of AS-associated genes, such as RUNX3, TNFRSF1A, and NPEPPS, were found to be highest in NK cells. Additionally, scDRS analysis using the human gut single-cell atlas revealed significant upregulation of AS-associated genes predominantly in NK cells. With co-localization analyses using a large-scale NK cell transcriptomic study with genotyped subjects, we found putative target genes for AS risk variants, including the widely studied ERAP1, previously reported as likely target gene TNFRSF1A and two new understudied target genes.

Conclusion: Using a variety of published datasets and complementary analytical approaches, we consistently identified NK cells as the primary cell type with gene expression and open chromatin enriched in genetic risk variants for AS. These findings point to NK cells as key mediators of the genetic susceptibility to AS.


Disclosures: M. Chiñas: None; D. Fernandez-Salinas: None; V. Aguiar: None; V. Caballero-Nieto: None; M. Lefton: None; J. Ermann: AbbVie, 2, 5, Boehringer Ingelheim, 5, Janssen, 2, Novartis, 2, 5, Pfizer, 2, 5, Takeda, 2, UCB Pharma, 2; M. Gutierrez-Arcelus: None.

To cite this abstract in AMA style:

Chiñas M, Fernandez-Salinas D, Aguiar V, Caballero-Nieto V, Lefton M, Ermann J, Gutierrez-Arcelus M. Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/integrative-functional-genomics-points-to-natural-killer-cells-as-key-drivers-in-the-pathogenesis-of-ankylosing-spondylitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/integrative-functional-genomics-points-to-natural-killer-cells-as-key-drivers-in-the-pathogenesis-of-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology